Search

Your search keyword '"Palmieri R"' showing total 541 results
Start Over Author "Palmieri R"
541 results on '"Palmieri R"'

1. Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis

Author

Cantoresi F, Caserini M, Bidoli A, Maggio F, Marino R, Carnevale C, Sorgi P, and Palmieri R

Subjects
Dermatology, RL1-803
Abstract

Franca Cantoresi,1 Maurizio Caserini,2 Antonella Bidoli,1 Francesca Maggio,1 Raffaella Marino,1 Claudia Carnevale,1 Paola Sorgi,1 Renata Palmieri21Department of Dermatology, Sapienza University, Rome, Italy; 2Scientific Department, Polichem SA, Lugano, Switzerland Background: Nail psoriasis occurs in up to 50% of patients affected by psoriasis, with a significant impact on quality of life that leads to a real clinical need for new therapeutic options. Aim: To confirm whether the strengthening and hardening properties of the hydroxypropyl-chitosan (HPCH) nail lacquer could improve the structure of the nail plates on psoriatic nails. Materials and methods: A randomized, double-blind, placebo controlled, parallel-group trial was carried out to evaluate the efficacy and tolerability of a hydrosoluble nail lacquer containing HPCH, Equisetum arvense, and methylsulfonylmethane on nail psoriasis. The test product or a placebo was applied once daily for 24 weeks to all fingernails. Efficacy assessments were performed on the target fingernail by means of the modified Nail Psoriasis Severity Index score. A cut-off score of 4 was considered to define the clinical cure rate (ie, Cure ≤4, Failure >4). Results: After 24 weeks, the clinical cure rate showed the statistically significant superiority of the HPCH nail lacquer compared to placebo in both the intention-to-treat (Fisher's exact test, P=0.0445) and the per protocol population (Fisher's exact test, P=0.0437). This superiority was already present after 16 weeks of treatment. Moreover, the analysis of the modified Nail Psoriasis Severity Index-50 showed a statistically significant clinical improvement after 12 weeks of treatment in comparison to the results obtained after 8 weeks (Fisher's exact test, P

Published
2014

3. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

Author

Maurillo, L., Spagnoli, A., Candoni, A., Papayannidis, C., Borlenghi, E., Lazzarotto, D., Fianchi, L., Sciumè, M., Zannier, M.E., Buccisano, F., Del Principe, M.I., Mancini, V., Breccia, M., Fanin, R., Todisco, E., Lunghi, M., Palmieri, R., Fracchiolla, N., Musto, P., Rossi, G., and Venditti, A.

Published
2023
Full Text
View/download PDF

4. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Author

Venditti, A, Piciocchi, A, Candoni, A, Arena, V, Palmieri, R, Fili, C, Carella, A, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Curti, A, Luppi, M, Ingrosso, C, Martelli, M, Cuneo, A, Albano, F, Mule, A, Tafuri, A, Cudillo, L, Tieghi, A, Fracchiolla, N, Capelli, D, Trisolini, S, Alati, C, La Sala, E, Maurillo, L, Del Principe, M, Consalvo, M, Divona, M, Ottone, T, Cerretti, R, Sconocchia, G, Voso, M, Fazi, P, Vignetti, M, Buccisano, F, Venditti A., Piciocchi A., Candoni A., Arena V., Palmieri R., Fili C., Carella A. M., Calafiore V., Cairoli R., De Fabritiis P., Storti G., Salutari P., Lanza F., Martinelli G., Curti A., Luppi M., Ingrosso C., Martelli M. P., Cuneo A., Albano F., Mule A., Tafuri A., Cudillo L., Tieghi A., Fracchiolla N. S., Capelli D., Trisolini S. M., Alati C., La Sala E., Maurillo L., Del Principe M. I., Consalvo M. A. I., Divona M. D., Ottone T., Cerretti R., Sconocchia G., Voso M. T., Fazi P., Vignetti M., Buccisano F., Venditti, A, Piciocchi, A, Candoni, A, Arena, V, Palmieri, R, Fili, C, Carella, A, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Curti, A, Luppi, M, Ingrosso, C, Martelli, M, Cuneo, A, Albano, F, Mule, A, Tafuri, A, Cudillo, L, Tieghi, A, Fracchiolla, N, Capelli, D, Trisolini, S, Alati, C, La Sala, E, Maurillo, L, Del Principe, M, Consalvo, M, Divona, M, Ottone, T, Cerretti, R, Sconocchia, G, Voso, M, Fazi, P, Vignetti, M, Buccisano, F, Venditti A., Piciocchi A., Candoni A., Arena V., Palmieri R., Fili C., Carella A. M., Calafiore V., Cairoli R., De Fabritiis P., Storti G., Salutari P., Lanza F., Martinelli G., Curti A., Luppi M., Ingrosso C., Martelli M. P., Cuneo A., Albano F., Mule A., Tafuri A., Cudillo L., Tieghi A., Fracchiolla N. S., Capelli D., Trisolini S. M., Alati C., La Sala E., Maurillo L., Del Principe M. I., Consalvo M. A. I., Divona M. D., Ottone T., Cerretti R., Sconocchia G., Voso M. T., Fazi P., Vignetti M., and Buccisano F.

Published
2024

6. The Push the button algorithm for contragredient Lie superalgebras

Author

Fioresi, R. and Palmieri, R.

Subjects
Mathematics - Representation Theory, Mathematics - Combinatorics, 17B22, 17B67
Abstract

The purpose of the present paper is to explain how the push the button algorithm can be successfully applied to the Vogan superdiagram associated to a contragredient Lie superalgebra, so to obtain the equivalent super version of the Borel-De Siebenthal Theorem.

Published
2016

10. ERAS program adherence-institutionalization, major morbidity and anastomotic leakage after elective colorectal surgery: the iCral2 multicenter prospective study

Author

Catarci, M, Ruffo, G, Viola, M, Pirozzi, F, Delrio, P, Borghi, F, Garulli, G, Baldazzi, G, Marini, P, Sica, G, Guercioni, G, Ciano, P, Benedetti, M, Cicconi, S, Marziali, I, Bertocchi, E, Altamura, A, Rubichi, F, Sciuto, A, Pace, U, Fares Bucci, A, Cianflocca, D, Migliore, M, Pirrera, B, Alagna, V, Cassini, D, Attinà, G, Arcudi, C, Sensi, B, Bucci, A, Campagnacci, R, Maurizi, A, Basti, M, Frazzini, D, Caracino, V, Pedrazzani, C, Turri, G, Mancini, S, Sagnotta, A, Scatizzi, M, Pandolfini, L, Falsetto, A, Baiocchi, G, Molfino, S, Totis, M, Braga, M, Liverani, A, Cesare, T, Scabini, S, Martino, A, Luca, R, Simone, M, Carrara, A, Tirone, G, Motter, M, Caricato, M, Capolupo, G, Amodio, P, Palmieri, R, Pavanello, M, Marco, C, Muratore, A, Marsanic, P, Patriti, A, Sisti, V, Lucchi, A, Martorelli, G, Clementi, M, Guadagni, S, Longo, G, Tomassini, F, Santoni, S, Vettoretto, N, Botteri, E, Armellini, A, Brisinda, G, Chiarello, M, Cariati, M, Berti, S, Gennai, A, Anania, G, Rubino, S, Siquini, W, Cardinali, A, Catarci M., Ruffo G., Viola M. G., Pirozzi F., Delrio P., Borghi F., Garulli G., Baldazzi G., Marini P., Sica G., Guercioni G., Ciano P., Benedetti M., Cicconi S., Marziali I., Bertocchi E., Altamura A., Rubichi F., Sciuto A., Pace U., Fares Bucci A., Cianflocca D., Migliore M., Pirrera B., Alagna V., Cassini D., Attinà G. M., Arcudi C., Sensi B., Bucci A. F., Campagnacci R., Maurizi A., Basti M., Frazzini D., Caracino V., Pedrazzani C., Turri G., Mancini S., Sagnotta A., Scatizzi M., Pandolfini L., Falsetto A., Baiocchi G. L., Molfino S., Totis M., Braga M., Liverani A., Cesare T. D., Scabini S., Martino A., Luca R. D., Simone M., Carrara A., Tirone G., Motter M., Caricato M., Capolupo G. T., Amodio P., Palmieri R. M., Pavanello M., Marco C. D., Muratore A., Marsanic P., Patriti A., Sisti V., Lucchi A., Martorelli G., Clementi M., Guadagni S., Longo G., Tomassini F., Santoni S., Vettoretto N., Botteri E., Armellini A., Brisinda G., Chiarello M. M., Cariati M., Berti S., Gennai A., Anania G., Rubino S., Siquini W., Cardinali A., Catarci, M, Ruffo, G, Viola, M, Pirozzi, F, Delrio, P, Borghi, F, Garulli, G, Baldazzi, G, Marini, P, Sica, G, Guercioni, G, Ciano, P, Benedetti, M, Cicconi, S, Marziali, I, Bertocchi, E, Altamura, A, Rubichi, F, Sciuto, A, Pace, U, Fares Bucci, A, Cianflocca, D, Migliore, M, Pirrera, B, Alagna, V, Cassini, D, Attinà, G, Arcudi, C, Sensi, B, Bucci, A, Campagnacci, R, Maurizi, A, Basti, M, Frazzini, D, Caracino, V, Pedrazzani, C, Turri, G, Mancini, S, Sagnotta, A, Scatizzi, M, Pandolfini, L, Falsetto, A, Baiocchi, G, Molfino, S, Totis, M, Braga, M, Liverani, A, Cesare, T, Scabini, S, Martino, A, Luca, R, Simone, M, Carrara, A, Tirone, G, Motter, M, Caricato, M, Capolupo, G, Amodio, P, Palmieri, R, Pavanello, M, Marco, C, Muratore, A, Marsanic, P, Patriti, A, Sisti, V, Lucchi, A, Martorelli, G, Clementi, M, Guadagni, S, Longo, G, Tomassini, F, Santoni, S, Vettoretto, N, Botteri, E, Armellini, A, Brisinda, G, Chiarello, M, Cariati, M, Berti, S, Gennai, A, Anania, G, Rubino, S, Siquini, W, Cardinali, A, Catarci M., Ruffo G., Viola M. G., Pirozzi F., Delrio P., Borghi F., Garulli G., Baldazzi G., Marini P., Sica G., Guercioni G., Ciano P., Benedetti M., Cicconi S., Marziali I., Bertocchi E., Altamura A., Rubichi F., Sciuto A., Pace U., Fares Bucci A., Cianflocca D., Migliore M., Pirrera B., Alagna V., Cassini D., Attinà G. M., Arcudi C., Sensi B., Bucci A. F., Campagnacci R., Maurizi A., Basti M., Frazzini D., Caracino V., Pedrazzani C., Turri G., Mancini S., Sagnotta A., Scatizzi M., Pandolfini L., Falsetto A., Baiocchi G. L., Molfino S., Totis M., Braga M., Liverani A., Cesare T. D., Scabini S., Martino A., Luca R. D., Simone M., Carrara A., Tirone G., Motter M., Caricato M., Capolupo G. T., Amodio P., Palmieri R. M., Pavanello M., Marco C. D., Muratore A., Marsanic P., Patriti A., Sisti V., Lucchi A., Martorelli G., Clementi M., Guadagni S., Longo G., Tomassini F., Santoni S., Vettoretto N., Botteri E., Armellini A., Brisinda G., Chiarello M. M., Cariati M., Berti S., Gennai A., Anania G., Rubino S., Siquini W., and Cardinali A.

Abstract

Background: Enhanced recovery after surgery (ERAS) programs influence morbidity rates and length of stay after colorectal surgery (CRS), and may also impact major complications and anastomotic leakage rates. A prospective multicenter observational study to investigate the interactions between ERAS program adherence and early outcomes after elective CRS was carried out. Methods: Prospective enrolment of patients submitted to elective CRS with anastomosis in 18 months. Adherence to 21 items of ERAS program was measured upon explicit criteria in every case. After univariate analysis, independent predictors of primary endpoints [major morbidity (MM) and anastomotic leakage (AL) rates] were identified through logistic regression analyses including all significant variables, presenting odds ratios (OR). Results: Institutional ERAS protocol was declared by 27 out of 38 (71.0%) participating centers. Median overall adherence to ERAS program items was 71.4%. Among 3830 patients included in the study, MM and AL rates were 4.7% and 4.2%, respectively. MM rates were independently influenced by intra- and/or postoperative blood transfusions (OR 7.79, 95% CI 5.46–11.10; p < 0.0001) and standard anesthesia protocol (OR 0.68, 95% CI 0.48–0.96; p = 0.028). AL rates were independently influenced by male gender (OR 1.48, 95% CI 1.06–2.07; p = 0.021), intra- and/or postoperative blood transfusions (OR 4.29, 95% CI 2.93–6.50; p < 0.0001) and non-standard resections (OR 1.49, 95% CI 1.01–2.22; p = 0.049). Conclusions: This study disclosed wide room for improvement in compliance to several ERAS program items. It failed to detect any significant association between institutionalization and/or adherence rates to ERAS program with primary endpoints. These outcomes were independently influenced by gender, intra- and postoperative blood transfusions, non-standard resections, and standard anesthesia protocol.

Published
2022

11. Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Author

Venditti, A, Piciocchi, A, Soddu, S, Frigeni, M, Palmieri, R, Borlenghi, E, Fracchiolla, N, Martelli, M, Audisio, E, Gianfaldoni, G, Vetro, C, di Rienzo, N, Esposito, D, Di Veroli, A, Selleri, C, Gigli, F, Curti, A, Mulè, A, Califano, C, Bigliardi, S, Breccia, M, Fozza, C, Bocchia, M, Lico, A, Simonetti, F, Pierdomenico, E, Buccisano, F, Del Principe, M, Maurillo, L, Fazi, P, Vignetti, M, Ferrara, F, Cairoli, R, Rossi, G, Rambaldi, A, Venditti, Adriano, Piciocchi, Alfonso, Soddu, Stefano, Frigeni, Marco, Palmieri, Raffaele, Borlenghi, Erika, Fracchiolla, Nicola, Martelli, Maria Paola, Audisio, Ernesta, Gianfaldoni, Giacomo, Vetro, Calogero, di Rienzo, Nicola, Esposito, Daniela, Di Veroli, Ambra, Selleri, Carmine, Gigli, Federica, Curti, Antonio, Mulè, Antonino, Califano, Catello, Bigliardi, Sara, Breccia, Massimo, Fozza, Claudio, Bocchia, Monica, Lico, Albana, Simonetti, Federico, Pierdomenico, Elisabetta, Buccisano, Francesco, Del Principe, Maria Ilaria, Maurillo, Luca, Fazi, Paola, Vignetti, Marco, Ferrara, Felicetto, Cairoli, Roberto, Rossi, Giuseppe, Rambaldi, Alessandro, Venditti, A, Piciocchi, A, Soddu, S, Frigeni, M, Palmieri, R, Borlenghi, E, Fracchiolla, N, Martelli, M, Audisio, E, Gianfaldoni, G, Vetro, C, di Rienzo, N, Esposito, D, Di Veroli, A, Selleri, C, Gigli, F, Curti, A, Mulè, A, Califano, C, Bigliardi, S, Breccia, M, Fozza, C, Bocchia, M, Lico, A, Simonetti, F, Pierdomenico, E, Buccisano, F, Del Principe, M, Maurillo, L, Fazi, P, Vignetti, M, Ferrara, F, Cairoli, R, Rossi, G, Rambaldi, A, Venditti, Adriano, Piciocchi, Alfonso, Soddu, Stefano, Frigeni, Marco, Palmieri, Raffaele, Borlenghi, Erika, Fracchiolla, Nicola, Martelli, Maria Paola, Audisio, Ernesta, Gianfaldoni, Giacomo, Vetro, Calogero, di Rienzo, Nicola, Esposito, Daniela, Di Veroli, Ambra, Selleri, Carmine, Gigli, Federica, Curti, Antonio, Mulè, Antonino, Califano, Catello, Bigliardi, Sara, Breccia, Massimo, Fozza, Claudio, Bocchia, Monica, Lico, Albana, Simonetti, Federico, Pierdomenico, Elisabetta, Buccisano, Francesco, Del Principe, Maria Ilaria, Maurillo, Luca, Fazi, Paola, Vignetti, Marco, Ferrara, Felicetto, Cairoli, Roberto, Rossi, Giuseppe, and Rambaldi, Alessandro

Published
2023

12. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, Todisco, Elisabetta, Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023

13. Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials

Author

Luciano, L., Latagliata, R., Gugliotta, G., Annunziata, M., Tiribelli, M., Martino, B., Sica, A., Esposito, M. R., Bocchia, M., Galimberti, S., Sora', Federica, Albano, F., Palmieri, R., Pregno, P., Dragani, M., Iovine, M., Sica, Simona, Iurlo, A., Castagnetti, F., Rosti, G., Breccia, M., Sora' F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), Luciano, L., Latagliata, R., Gugliotta, G., Annunziata, M., Tiribelli, M., Martino, B., Sica, A., Esposito, M. R., Bocchia, M., Galimberti, S., Sora', Federica, Albano, F., Palmieri, R., Pregno, P., Dragani, M., Iovine, M., Sica, Simona, Iurlo, A., Castagnetti, F., Rosti, G., Breccia, M., Sora' F. (ORCID:0000-0002-9607-5298), and Sica S. (ORCID:0000-0003-2426-3465)

Abstract

Here, we report real-world evidence on the safety and efficacy of nilotinib as a first-line treatment in elderly patients with chronic phase CML, treated in 18 Italian centers. Sixty patients aged > 65 years (median age 72 years (65–84)) were reported: 13 patients were older than 75 years. Comorbidities were recorded at baseline in 56/60 patients. At 3 months of treatment, all patients obtained complete hematological response (CHR), 43 (71.6%) an early molecular response (EMR), while 47 (78%) reached a complete cytogenetic response (CCyR). At last follow-up, 63.4% of patients still had a deep molecular response (MR4 or better), 21.6% reached MR3 as best response and 11.6% persisted without MR. Most patients (85%) started the treatment at the standard dose (300 mg BID), maintained at 3 months in 80% of patients and at 6 months in 89% of them. At the last median follow-up of 46.3 months, 15 patients discontinued definitively the treatment (8 due to side effects, 4 died for unrelated CML causes, 1 for failure, 2 were lost to follow-up). One patient entered in treatment-free remission. As to safety, 6 patients (10%) experienced cardiovascular events after a median time of 20.9 months from the start. Our data showed that nilotinib could be, as first-line treatment, effective and relatively safe even in elderly CML patients. In this setting, more data in the long term are needed about possible dose reduction to improve the tolerability, while maintaining the optimal molecular response.

Published
2023

19. P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME

Author

Genovese, E., primary, Mirabile, M., additional, Rontauroli, S., additional, Sartini, S., additional, Fantini, S., additional, Tavernari, L., additional, Maccaferri, M., additional, Guglielmelli, P., additional, Bianchi, E., additional, Parenti, S., additional, Carretta, C., additional, Mallia, S., additional, Castellano, S., additional, Colasante, C., additional, Balliu, M., additional, Bartalucci, N., additional, Palmieri, R., additional, Ottone, T., additional, Mora, B., additional, Potenza, L., additional, Passamonti, F., additional, Voso, M. T., additional, Luppi, M., additional, Vannucchi, A. M., additional, Tagliafico, E., additional, and Manfredini, R., additional

Published
2022
Full Text
View/download PDF

20. P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS

Author

Sartini, S., primary, Fantini, S., additional, Rontauroli, S., additional, Mirabile, M., additional, Bianchi, E., additional, Badii, F., additional, Maccaferri, M., additional, Guglielmelli, P., additional, Ottone, T., additional, Palmieri, R., additional, Genovese, E., additional, Carretta, C., additional, Parenti, S., additional, Mallia, S., additional, Tavernari, L., additional, Salvadori, C., additional, Gesullo, F., additional, Maccari, C., additional, Zizza, M., additional, Grande, A., additional, Salmoiraghi, S., additional, Mora, B., additional, Potenza, L., additional, Rosti, V., additional, Passamonti, F., additional, Rambaldi, A., additional, Voso, M. T., additional, Mecucci, C., additional, Tagliafico, E., additional, Luppi, M., additional, Vannucchi, A. M., additional, and Manfredini, R., additional

Published
2022
Full Text
View/download PDF

21. PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS

Author

Paterno, G., primary, Palmieri, R., additional, Forte, V., additional, Bonanni, F., additional, Guarnera, L., additional, Mallegni, F., additional, Pascala, M. R., additional, Elisa, B., additional, Moretti, F., additional, Savi, A., additional, Maurillo, L., additional, Buccisano, F., additional, Venditti, A., additional, and Del Principe, M. I., additional

Published
2022
Full Text
View/download PDF

22. Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial

Author

Buccisano, F, Palmieri, R, Piciocchi, A, Arena, V, Maurillo, L, Del Principe, M, Paterno, G, Irno-Consalvo, M, Ottone, T, Divona, M, Conti, C, Fraboni, D, Lavorgna, S, Arcese, W, Voso, Mt, and Venditti, A

Subjects
measurable residual disease, Acute myeloid leukemia, immunophenotyping, minimal residual disease, Acute myeloid leukemia, minimal residual disease, measurable residual disease, immunophenotyping, Settore MED/15
Published
2022

23. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Author

Buccisano, F, Palmieri, R, Piciocchi, A, Arena, V, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, de Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Capria, S, Maurillo, L, Del Principe, M, Paterno, G, Consalvo, M, Ottone, T, Lavorgna, S, Voso, M, Fazi, P, Vignetti, M, Arcese, W, Venditti, A, Del Principe, MI, Consalvo, MAI, Voso, MT, Buccisano, F, Palmieri, R, Piciocchi, A, Arena, V, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, de Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Capria, S, Maurillo, L, Del Principe, M, Paterno, G, Consalvo, M, Ottone, T, Lavorgna, S, Voso, M, Fazi, P, Vignetti, M, Arcese, W, Venditti, A, Del Principe, MI, Consalvo, MAI, and Voso, MT

Abstract

The 2017 version of the European LeukemiaNet (ELN) recommendations, by integrating cytogenetics and mutational status of specific genes, divides patients with acute myeloid leukemia into 3 prognostically distinct risk categories: favorable (ELN2017-FR), intermediate (ELN2017-IR), and adverse (ELN2017-AR). We performed a post hoc analysis of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population. In this trial, after induction and consolidation, patients in complete remission were to receive an autologous stem cell transplant (auto-SCT) if categorized as favorable risk or an allogeneic stem cell transplant (allo-SCT) if adverse risk. Intermediate-risk patients were to receive auto-SCT or allo-SCT based on the postconsolidation levels of measurable residual disease as measured by using flow cytometry. Risk categorization was originally conducted according to the 2009 National Comprehensive Cancer Network recommendations. Among 500 patients, 445 (89%) were reclassified according to the ELN2017 criteria: ELN2017-FR, 186 (41.8%) of 455; ELN2017-IR, 179 (40.2%) of 445; and ELN2017-AR, 80 (18%) of 455. In 55 patients (11%), ELN2017 was not applicable. Two-year overall survival (OS) was 68.8%, 51.3%, 45.8%, and 42.8% for the ELN2017-FR, ELN2017-IR, ELN2017-not classifiable, and ELN2017-AR groups, respectively (P, .001). When comparing the 2 different transplant strategies in each ELN2017 risk category, a significant benefit of auto-SCT over allo-SCT was observed among ELN2017-FR patients (2-year OS of 83.3% vs 66.7%; P 5 .0421). The 2 transplant procedures performed almost equally in the ELN2017-IR group (2-year OS of 73.9% vs 70.8%; P 5 .5552). This post hoc analysis of the GIMEMA AML1310 trial confirms that the ELN2017 classification is able to accurately discriminate patients with different outcomes and who may benefit from different transplant strategies. Th

Published
2022

24. CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML

Author

Travaglini, S., Ottone, T., Angelini, D. F., Fiori, V., Dominici, S., Noguera, N. I., Sniegocka, M., Antonelli, S., Irno Consalvo, M. A., De Bardi, M., Banella, C., Divona, M., Marchesi, F., Masciarelli, Silvia, Fazi, F., Pieraccioli, M., Palmieri, R., De Angelis, G., Buccisano, F., Venditti, A., Battistini, L., Magnani, M., Voso, M. T., Masciarelli S., Travaglini, S., Ottone, T., Angelini, D. F., Fiori, V., Dominici, S., Noguera, N. I., Sniegocka, M., Antonelli, S., Irno Consalvo, M. A., De Bardi, M., Banella, C., Divona, M., Marchesi, F., Masciarelli, Silvia, Fazi, F., Pieraccioli, M., Palmieri, R., De Angelis, G., Buccisano, F., Venditti, A., Battistini, L., Magnani, M., Voso, M. T., and Masciarelli S.

Abstract

Acute Myeloid Leukemia with FLT3 internal tandem duplication mutations (FLT3-ITDmut AML) is an aggressive leukemia character- ized by heterogeneous genetic landscape [1]. Despite significant advances in AML therapy, the relapse rate remains high, due to the emergence of resistant clones, possibly involving leukemic stem cells (LSCs) [2]. This highlights the unmet need for deeper understanding of the molecular and immunophenotypic land- scape of LSCs in FLT3-ITDmut AML. We previously identified a population of leukemic precursor cells (LPCs), present at the time of initial AML diagnosis, characterized by the CD34/CD123/CD25/ CD99+ immunophenotype, and predictive for FLT3-ITDmut positivity [3]. In particular, these cells overexpress CD99 antigen, which may represent a target for monoclonal antibody (mAb) treatment [4]

Published
2022

31. The management of adult congenital heart disease in the emergency department. The Task Force from the Italian Society of Pediatric Cardiology and Congenital Heart Disease

Author

Gagliardi M. G., Barracano R., Palmieri R., Chessa M., Ferraris L., Sarubbi B., D'Alto M., Assenza G. E., Donti A., Gagliardi, M. G., Barracano, R., Palmieri, R., Chessa, M., Ferraris, L., Sarubbi, B., D'Alto, M., Assenza, G. E., and Donti, A.

Subjects
Adult, Heart Defects, Congenital, Emergency department, Cardiology, Eisenmenger syndrome, Heart failure, Arrhythmias, Cardiac, Arrhythmias, Italy, Pregnancy, Humans, Adult congenital heart disease, Infective endocarditis, Child, Emergency Service, Hospital
Abstract

Over recent years, thanks to remarkable advances in pediatric cardiology, cardiac surgery and catheter interventions, survival of children with congenital heart disease has significantly increased with the majority of patients surviving into adulthood. Therefore, the prevalence of adult patients with congenital heart disease has dramatically increased, as well as the need for specific and dedicated programs. Acute heart failure, infective endocarditis and arrhythmias represent the most common causes of visit in the emergency department in this population. Our task force aimed at guiding physicians taking care of this peculiar cohort of patients in the emergency department.

Published
2021

34. The impact of synchronous liver resection on the risk of anastomotic leakage following elective colorectal resection. A propensity score match analysis on behalf of the iCral study group

Author

Guerra, Francesco, primary, Petrelli, Filippo, additional, Greco, Paola Antonella, additional, Sisti, Valerio, additional, Catarci, Marco, additional, Montalti, Roberto, additional, Patriti, Alberto, additional, Alagna, V., additional, Amodio, P., additional, Anania, G., additional, Angeloni, R., additional, Arici, E., additional, Baiocchi, G., additional, Baraghini, M., additional, Benedetti, M., additional, Bertocchi, E., additional, Borghi, F., additional, Brisinda, G., additional, Campagnacci, R., additional, Capolupo, G.T., additional, Caricato, M., additional, Carrara, A., additional, Ceccaroni, M., additional, Chiarello, M.M., additional, Cianflocca, D., additional, Ciano, P., additional, Cicconi, S., additional, Clementi, M., additional, Delrio, P., additional, Di Cesare, T., additional, Di Marco, C., additional, Falsetto, A., additional, Garulli, G., additional, Guadagni, S., additional, Guercioni, G., additional, Lambertini, M., additional, Liverani, A., additional, Longo, G., additional, Lucchi, A., additional, Luzzi, A.P., additional, Macarone Palmieri, R., additional, Mancini, S., additional, Marini, P., additional, Marsanic, P., additional, Martino, A., additional, Martorelli, G., additional, Marziali, I., additional, Maurizi, A., additional, Migliore, M., additional, Molfino, S., additional, Motter, M., additional, Muratore, A., additional, Pace, U., additional, Pandolfini, L., additional, Pavanello, M., additional, Pirozzi, F., additional, Ruffo, G., additional, Ruggeri, B., additional, Sagnotta, A., additional, Santoni, S., additional, Scabini, S., additional, Scatizzi, M., additional, Sciuto, A., additional, Sica, G., additional, Tirone, G., additional, Tomassini, F., additional, Vettoretto, N., additional, and Zigiotto, D., additional

Published
2021
Full Text
View/download PDF

37. What makes you fupy ('food' + 'happy')? leveraging strategic maneuvering to build food coaching apps

Author

Musi, E., Palmieri, R., Mercuri, C., Giudici, A., Maiden, N., Hardman, C., and Borgo, R.

Subjects
HD, HV, TX, HM, GF
Abstract

Recommendation systems (RS) play a crucial role in influencing our daily decision-making practices and choices, such as healthy diets. However, arguments in support of a diet recommendation, which are embedded in the algorithmic design of the RS, tend to be redundant, and predominantly based on the past choices of the users or their peers, thus hindering rather than encouraging innovation and creativity. Such arguments are, thus, not effective when changes in users' habits are the goal, as in digital food coaching. To better inform the design of RS, we propose to conceive of human-computer interaction with RS as a strategic maneuvering, that is an argumentative exchange aimed at improving users' critical decision-making process while persuading them to keep up a healthy diet. Strategic maneuvering is accomplished at three levels: Selection from the topical potential, adaptation to audience demand and display of presentational devices. Based on the results of a study including a quantitative questionnaire to and a focus groups with Italian mothers living in the UK (35-45 years old), we show how audience demand (perceived food qualities) and presentational devices (naming of recipe categories) can be exploited when selecting what recipes (topical potential) to recommend in order to trigger creativity and help users achieve a healthier diet.

Published
2021

38. Ponatinib and Risk of Thrombotic Events: In Vitro Study on Platelet Functions

Author

Straface, E, Del Principe, Mi, Paterno, G, Gambardella, L, Buzzatti, E, Vona, R, Palmieri, R, Menna, P, Cittadini, C, Del Principe, D, and Venditti, A

Subjects
chemistry.chemical_compound, chemistry, business.industry, Ponatinib, Medicine, In vitro study, Platelet, Pharmacology, business, Settore MED/15
Published
2021

39. The impact of synchronous liver resection on the risk of anastomotic leakage following elective colorectal resection. A propensity score match analysis on behalf of the iCral study group

Author

Guerra, Paola Ofelia Francesca, Petrelli, F., Greco, P. A., Sisti, V., Catarci, Marco, Montalti, R., Patriti, A., Alagna, V., Amodio, P., Anania, G., Angeloni, Riccardo, Arici, E., Baiocchi, G., Baraghini, M., Benedetti, Marta, Bertocchi, E., Borghi, F., Brisinda, Giuseppe, Campagnacci, R., Capolupo, G. T., Caricato, M., Carrara, A., Ceccaroni, Marcello, Chiarello, M. M., Cianflocca, D., Ciano, P., Cicconi, S., Clementi, Maria Elisabetta, Delrio, P., Di Cesare, Tiziana, Di Marco, C., Falsetto, A., Garulli, G., Guadagni, S., Guercioni, G., Lambertini, M., Liverani, Antonio Maria Nicola, Longo, G., Lucchi, A., Luzzi, A. P., Macarone Palmieri, Raffaele, Mancini, S., Marini, P., Marsanic, P., Martino, A., Martorelli, G., Marziali, I., Maurizi, A., Migliore, M., Molfino, S., Motter, M., Muratore, A., Pace, U., Pandolfini, L., Pavanello, M., Pirozzi, F., Ruffo, G., Ruggeri, B., Sagnotta, A., Santoni, S., Scabini, S., Scatizzi, M., Sciuto, A., Sica, Gigliola, Tirone, G., Tomassini, F., Vettoretto, N., Zigiotto, D., Guerra F., Catarci M., Angeloni R., Benedetti M., Brisinda G. (ORCID:0000-0001-8820-9471), Ceccaroni M., Clementi M., Di Cesare T., Liverani A., Macarone Palmieri R., Sica G. (ORCID:0000-0002-7231-9139), Guerra, Paola Ofelia Francesca, Petrelli, F., Greco, P. A., Sisti, V., Catarci, Marco, Montalti, R., Patriti, A., Alagna, V., Amodio, P., Anania, G., Angeloni, Riccardo, Arici, E., Baiocchi, G., Baraghini, M., Benedetti, Marta, Bertocchi, E., Borghi, F., Brisinda, Giuseppe, Campagnacci, R., Capolupo, G. T., Caricato, M., Carrara, A., Ceccaroni, Marcello, Chiarello, M. M., Cianflocca, D., Ciano, P., Cicconi, S., Clementi, Maria Elisabetta, Delrio, P., Di Cesare, Tiziana, Di Marco, C., Falsetto, A., Garulli, G., Guadagni, S., Guercioni, G., Lambertini, M., Liverani, Antonio Maria Nicola, Longo, G., Lucchi, A., Luzzi, A. P., Macarone Palmieri, Raffaele, Mancini, S., Marini, P., Marsanic, P., Martino, A., Martorelli, G., Marziali, I., Maurizi, A., Migliore, M., Molfino, S., Motter, M., Muratore, A., Pace, U., Pandolfini, L., Pavanello, M., Pirozzi, F., Ruffo, G., Ruggeri, B., Sagnotta, A., Santoni, S., Scabini, S., Scatizzi, M., Sciuto, A., Sica, Gigliola, Tirone, G., Tomassini, F., Vettoretto, N., Zigiotto, D., Guerra F., Catarci M., Angeloni R., Benedetti M., Brisinda G. (ORCID:0000-0001-8820-9471), Ceccaroni M., Clementi M., Di Cesare T., Liverani A., Macarone Palmieri R., and Sica G. (ORCID:0000-0002-7231-9139)

Abstract

Introduction: how best to manage patients with colorectal cancer and synchronous liver metastasis is still controversial, with specific concerns of increased risk of postoperative complications following combined resection. We aimed at analyzing the influence of combined liver resection on the risk of anastomotic leak (AL) following colorectal resection. Methods: we reviewed the iCral prospectively maintained database to compare the relative risk of AL of patients undergoing colorectal resection for cancer to that of patients receiving simultaneous liver and colorectal resection for cancer with isolated hepatic metastases. The incidence of AL was the primary outcome of the analysis. Perioperative details and postoperative complications were also appraised. Results: out of a total of 996 patients who underwent colorectal resection for cancer, 206 receiving isolated colorectal resection were compared with a matched group of 53 patients undergoing simultaneous liver and colorectal resection. Combined surgery had greater operative time and resulted in longer postoperative hospitalization compared to colorectal resection alone. The proportion of overall morbidity following combined resection was significantly higher than after isolated colorectal resection (56.6% vs. 37.9%, p = 0.021). Overall, the two groups of patients did not differ neither on the rate of major postoperative complications, nor in terms of AL (9.4% vs. 6.3%, p = 0.381). At specific multivariate analysis, the duration of surgery was the only risk factor independently associated with the likelihood of AL. Conclusions: combining hepatic with colorectal resection for the treatment of synchronous liver metastasis from colorectal cancer does not increase significantly the incidence of AL.

Published
2021

46. Impact of implementation of the ERAS program in colorectal surgery: a multi-center study based on the “Lazio Network” collective database

Author

Grieco, M., Lorenzon, Laura, Pernazza, G., Carlini, M., Brescia, A., Santoro, R., Crucitti, Antonio, Palmieri, R. M., Santoro, E., Stipa, F., Sacchi, M., Persiani, Roberto, Lorenzon L. (ORCID:0000-0001-6736-0383), Crucitti A. (ORCID:0000-0003-3496-4185), Persiani R. (ORCID:0000-0002-1537-5097), Grieco, M., Lorenzon, Laura, Pernazza, G., Carlini, M., Brescia, A., Santoro, R., Crucitti, Antonio, Palmieri, R. M., Santoro, E., Stipa, F., Sacchi, M., Persiani, Roberto, Lorenzon L. (ORCID:0000-0001-6736-0383), Crucitti A. (ORCID:0000-0003-3496-4185), and Persiani R. (ORCID:0000-0002-1537-5097)

Abstract

Background: ERAS implementation improved outcomes in patients undergoing colorectal surgery. The process of incorporating this pathway in clinical practice may be challenging. This observational study investigated the impact of systematic ERAS implementation on surgical outcomes in patients undergoing colorectal resections in a regional network of 10 institutions. Methods: Implementation of ERAS pathway was designed using regular audits and a common protocol. All patients undergoing elective colorectal surgery between 2016 and 2017 were considered eligible. A collective database including 18 ERAS items, clinical and surgical data, and outcomes was designed. Univariate and multivariate analyses were performed for the following outcomes: morbidity, anastomotic leak, reinterventions, hospital stay, and readmissions. Results: A total of 827 patients were included, and a mean of 11.3 ERAS items applied/patient was reported. Logistic regression indicated that an increased number of ERAS items applied reduced overall and severe morbidity (OR 0.86 and 0.87, respectively 95%CI 0.8197–0.9202 and 95%CI 0.7821–0.9603), hospitalization (OR 0.53 95%CI 0.4917–0.5845) and reinterventions (OR 0.84 95%CI 0.7536–0.9518) in the entire series. The same results were obtained for a prolonged hospitalization differentiating right-sided (OR 0.48 95%CI 0.4036–0.5801), left-sided (OR 0.48 95%CI 0.3984–0.5815), and rectal resections (OR 0.46 95%CI 0.3753–0.5851). An inverse correlation was found between the application of ERAS items and morbidity in right-sided and rectal procedures (OR 0.89 and 0.84, respectively 95%CI 0.7976–0.9773 and 95%CI 0.7418–0.9634). Conclusions: Systematic implementation of the ERAS pathway using multi-institutional audits can increase protocol adherence and improve surgical outcomes in patients undergoing colorectal surgery.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results